# Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

> **NCT02429375** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Mocetinostat Plus Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT02429375
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-22
- **Primary completion:** 2021-02-17
- **Final completion:** 2021-02-17
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429375, "Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02429375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*